Technology | March 06, 2015

ACC Guideline App Upgrade Includes Full Set of Prevention Guidelines

App provides mobile access to guidelines, tools for treatment, heart disease prevention information

ACC, Guideline App, prevention, atrial fibrillation, clinical decision support

March 6, 2015 — The American College of Cardiology (ACC) has launched version 2.0 of their Guideline Clinical App. With the addition of the healthy lifestyle and obesity guidelines, the app now contains the full set of clinical prevention guidelines released by ACC/American Heart Association in 2013. These additions expand the collection of clinical guidelines in the app, which already includes guidelines on assessment of cardiovascular risk, treatment of blood cholesterol, atrial fibrillation, heart failure and valvular heart disease.

ACC’s Guideline Clinical App was developed to serve as a mobile home for all ACC/AHA guideline content and related tools. It includes an executive summary and top 10 points for each guideline, as well as a collection of interactive tools such as dosing calculators, scoring tools and algorithms useful to clinicians in determining recommended care

The original version of the app was launched in November 2014, with a second content release in December 2014. Version 2.0 of the app is part of a plan to continuously add guideline content, upgrade functionality and roll out fixes in response to user feedback. More guideline content and improvements are planned throughout 2015. ACC is conducting an impact and evaluation study to help inform future plans for the app. 

The ACC Guideline Clinical App is available for free and can be downloaded to a tablet or smartphone from iTunes and GooglePlay. 

For more information: www.acc.org

Related Content

MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension| September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Overlay Init